

## Phase 1/2 Study of Vilastobart (XTX101), a Tumor-Activated, Fc-enhanced Anti-CTLA-4 Monoclonal Antibody, in Combination with Atezolizumab in Patients with Advanced Solid Tumors and in MSS CRC

J. Randolph Hecht<sup>1</sup>, Diwakar Davar<sup>2</sup>, Marwan Fakih<sup>3</sup>, Tanios Bekaii-Saab<sup>4</sup>, Nicholas Devito<sup>5</sup>, John George Knecht<sup>6</sup>, Andrae Lavon Vandross<sup>7</sup>, Cesar Augusto Perez<sup>8</sup>, Alberto Bessudo<sup>9</sup>, Anurag Gupta<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Katarina Luptakova<sup>10</sup>, Aparna Parikh<sup>11</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Sattanathan Paramasivan<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Sonali Garg<sup>10</sup>, Myra Popejoy<sup>10</sup>, Bruce Dezube<sup>10</sup>, Scott McConnell<sup>10</sup>, Sonali Garg<sup>10</sup>, Scott McConnell<sup>10</sup>, Scott McConnell<sup></sup> (10) Xilio Therapeutics, Inc., Waltham, MA; (11) Massachusetts General Hospital, Boston, MA.

(1) UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; (2) UPMC Hillman Cancer Center, Duarte, CA; (3) City of Hope Comprehensive Cancer Center, Durham, NC; (6) Tranquil Clinical Research, Webster, TX; (7) NEXT Oncology, Austin, TX; (8) Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA; (1) UPMC Hillman Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA; (1) UPMC Hillman Cancer Center, Duarte, CA; (2) UPMC Hillman Cancer Center, Duarte, CA; (3) City of Hope Comprehensive Cancer Center, Duarte, CA; (4) Mayo Clinic, Phoenix, AZ; (5) Duke University Medical Center, Duarte, CA; (4) Mayo Clinic, Phoenix, AZ; (5) Duke University Research, Webster, TX; (7) NEXT Oncology, Austin, TX; (8) Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA;



- Intratumoral Treg depletion observed in a tumor biopsy from a MSS CRC patient was consistent with the intended mechanism of action of vilastobart
- Dose level of vilastobart 100 mg Q6W in combination with atezolizumab (1200 mg Q3W) was declared the initial RP2D
- Across all vilastobart dose levels (75-150 mg), minimal irAEs observed, colitis of any grade was experienced in 5% of patients (1 patient with Grade 3)
- No Grade 4 or 5 TRAEs at any dose level in Phase 1C



## **RESULTS OF PHASE 2** Combination of Vilastobart (100 mg Q6W) and Atezolizumab (1200 mg Q3W)

## Phase 2 Enrolled Heavily Pre-Treated MSS Colorectal Cancer Patients With and Without Liver Metastases

Patient Characteristics	Total (N=40)	Patient Characteristics	Total (N=40)	Treatment Status
Demographics		Drien Lines of Anti Conser Treatment	Median 4	Continuing on Treatment
Age, median (range)	55 (25-82)	Prior Lines of Anti-Cancer Treatmen	(range 1-10)	Discontinued Treatment
Female	20 (50%)	unknown	2 (5%)	Disease Progression
ECOG PS 0	17 (43%)	1	5 (13%)	Clinical Progression
ECOG PS 1	23 (58%)	2	5 (13%)	Adverse Events
Tumor Types		3	7 (18%)	
MSS CRC	40	4	6 (15%)	70% of patients had 3 or more
Patients with liver metastases	16	5	7 (18%)	prior lines of treatment
Patients without liver metastases	24	6 or more	8 (20%)	

Data cutoff date: January 13, 2025

Abbreviations: ADCC: antibody-dependent cell-mediated cytotoxicity; AE: adverse event; ALT: alanine aminotransferase; BOR: best overall response; C#D#: Cycle # Day #; CEA: Carcinoembryonic Antigen; CRC: colorectal cancer; ctDNA: Circulating Tumor DNA; CTLA-4: cytotoxic T-Lymphocyte Associated Protein 4; DCR: disease control rate; dMMR: deficient mismatch repair; ECOG PS: Eastern Cooperative Oncology Group Performance Status; Fc: fraction crystallizable; FcyR: fraction crystallizable gamma receptor; irAE: immune-related adverse event; mAb: monoclonal antibody; MMP: matrix metalloprotease; MSI-H: microsatellite instability-high; MSS: microsatellite instability-high; MSS: microsatellite stable; NSCLC: non-small cell lung cancer; ORR: objective response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligan regulatory T-cell.



Total (N=40)	
23	
17	
6	
8	
3	

- Vilastobart (XTX101) is a novel tumor-activated, high affinity binding, Fc-enhanced anti-CTLA-4 mAb that is designed to focus activity
- Clinical data to date suggest that vilastobart has a differentiated safety profile from systemically active anti-CTLA-4, consistent with tumor-selective
- In Phase 1C, one patient with MSS CRC has an ongoing PR (confirmed) with resolution of liver metastases
- The combination of vilastobart and atezolizumab showed anti-tumor activity in MSS CRC where previously PD(L)-1 inhibitors and first generation anti-
- 3 PRs (2 confirmed, 1 pending confirmation) in patients with MSS CRC without liver metastases:
- 1 ongoing response with normalization of CEA accompanied by undetectable ctDNA following treatment
- An additional MSS CRC patient without liver metastases had a 24% tumor reduction at their initial 9-week assessment and is ongoing on therapy
- In Phase 2, the combination of vilastobart (100 mg Q6W) and atezolizumab (1200 mg Q3W) has been observed to be generally well-tolerated in patients

- These initial data support the further development of the combination of vilastobart and atezolizumab in patients with MSS CRC

# Combination for Vilastobart (100 mg Q6W) and Atezolizumab (1200 mg Q3W)

## Combination of Vilastobart (XTX101) and Atezolizumab Demonstrated Anti-Tumor Activity in MSS CRC Patients

## 27% ORR in Patients With MSS CRC Without Liver Metastases<sup>‡</sup>

- 40 patients with MSS CRC enrolled in ongoing Phase 2
- 18 patients response-evaluable with at least 1 scan reported

Best Response	Without Liver Metastases (n = 11 response-evaluable)	With Liver Metastases (n = 7 response-evaluable)
PR	3 <sup>‡</sup>	0
SD	3	1
ORR	27% <sup>‡</sup>	0%
DCR*	55%	14%

‡ Includes 2 confirmed PRs (see Patient A and Patient B vignettes) and 1 unconfirmed PR (pending confirmation, see Patient C

\* DCR is defined as PR or SD through the first on treatment imaging scan as defined by the protocol (~9 weeks)

16 Weeks from First Dose Combination of Vilastobart (XTX101) and Atezolizumab Was

## Generally Well-Tolerated in Phase 2


- 6 patients experienced Grade 3/4 TRAEs (related to vilastobart or atezolizumab)
- Only 2 Grade 4 TRAEs (thrombocytopenia and neutropenia, 1 each)
- No Grade 5 TRAEs

AE Category / Term All TRAEs with ≥10% incidence or Grade 3/4 TRAE with ≥ 5
Fatigue
Diarrhea
Infusion related reactions
Related to vilastobart
Related to atezolizumab
Pyrexia
ALT increased
AST increased
Colitis
Vilastobart dose reduction due to AE*
Treatment discontinuation due to TRAE <sup>A</sup>
TRAEs are related to vilastobart or atezolizumab

Dose reduction of atezolizumab is not permitted per protocol Reflects discontinuation of both vilastobart and atezolizumat

Non-laboratory Grade 3 TRAEs not included in the table above consisted of: maculopapular rash and febrile neutropenia in 1 patient; lower gastrointestinal hemorrhage in 1 patient with thrombocytopenia;

and 1 patient with Triple M overlap syndrome (myocarditis, myositis and myasthenia gravis).



. Bullock et al. ESMO GI 2023 Davar et al. ESMO IO 2023

References

4. Davar et al, SITC 2024, data updated as of Jan 6<sup>th</sup>, 2025 5. Sahin et al, 2022 ASCO Educational Book



1. Jenkins et al., J Immunother Cancer 2023 Dec 12;11(12):e007785